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Objective: Intimal hyperplasia is a vascular remodelling process that occurs after a vascular injury. The mechanisms
involved in intimal hyperplasia are proliferation, dedifferentiation, and migration of medial smooth muscle cells towards
the subintimal space. We postulated that gap junctions, which coordinate physiologic processes such as cell growth and
differentiation, might participate in the development of intimal hyperplasia. Connexin43 (Cx43) expression levels may be
altered in intimal hyperplasia, and we therefore evaluated the regulated expression of Cx43 in human saphenous veins in
culture in the presence or not of fluvastatin, an inhibitor of 3-hydroxy-3-methylglutaryl-coenzyme A reductase activity.
Methods: Segments of harvested human saphenous veins, obtained at the time of bypass graft, were opened longitudinally
with the luminal surface uppermost and maintained in culture for 14 days. Vein fragments were then processed for
histologic examination, neointimal thickness measurements, immunocytochemistry, RNA, and proteins analysis.
Results: Of the four connexins (Cx37, 40, 43, and 45), we focused on Cx43 and Cx40, which we found by real-time
polymerase chain reaction to be expressed in the saphenous vein because they are the predominant connexins expressed by
smooth muscle cells and endothelial cells. After 14 days of culture, histomorphometric analysis showed a significant
increase in the intimal thickness as observed during the process of intimal hyperplasia. A time-course analysis revealed a
progressive upregulation of Cx43 to reach a maximal increase of sixfold to eightfold at both transcript and protein levels
after 14 days in culture. In contrast, the expression of Cx40, abundantly expressed in the endothelial cells, was not altered.
Immunofluorescence showed a large increase in Cx43 within smooth muscle cell membranes of the media layer. The
development of intimal hyperplasia in vitro was decreased in presence of fluvastatin and was associated with reduced Cx43
expression.
Conclusions: These data show that Cx43 is increased in vitro during the process of intimal hyperplasia and that fluvastatin
could prevent this induction, supporting a critical role for Cx43-mediated gap-junctional communication in the human
vein during the development of intimal hyperplasia. ( J Vasc Surg 2005;41:1043-52.)
Clinical Relevance: Stenosis due to intimal hyperplasia is the most common cause of failure of venous bypass grafts. To
better understand the development of intimal hyperplasia, we used an ex vivo organ culture model to study saphenous
veins harvested from patients undergoing a lower limb bypass surgery. In this model, the morphologic and functional
integrity of the vessel wall is maintained and significant intimal hyperplasia development occurs after 14 days in culture.
We have postulated that gap junctions, which coordinate physiologic processes such as cell growth and differentiation,
may participate in the development of intimal hyperplasia. Indeed, intimal hyperplasia consists of proliferation and
migration of smooth muscle cells into the subendothelial space. Intercellular communication is responsible for the direct
transfer of ions and small molecules from one cell to the other through gap-junction channels found at cell-cell
appositions. No study to date has evaluated whether gap junctional communication is involved in the process of intimal
hyperplasia in humans. This assertion was investigated by using the aforementioned organ culture model of intimal
hyperplasia in human saphenous veins, and our data support a critical role for Cx43-mediated gap junctional commu-
nication in human vein during the development of intimal hyperplasia.Stenosis in venous bypass grafts corresponding to inti-
mal hyperplasia is a vascular pathophysiologic feature that
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doi:10.1016/j.jvs.2005.02.036may result in occlusion of the vessel lumen.1,2 Graft wall
remodelling is caused by adaptation of the vein to extrinsic
factors such as modified shear stress,3 wall tension,3 endo-
thelial damage,4 and platelet activation.5-7 Intrinsic prop-
erties of endothelial cells and medial smooth muscle cells
are also involved in intimal hyperplasia development by
secreting factors such as platelet-derived growth factor,5-7
fibroblast growth factor,8 and insulin-like growth factor.4
These different factors are implicated in proliferation and
migration of medial smooth muscle cells into the subinti-
mal space and are associated with a phenotypic modifica-
tion of smooth muscle cells. From a quiescent contractile
state, the activated smooth muscle cells become prolifera-
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June 20051044 Déglise et altive and synthetic.9,10 Thus, smooth muscle cells produce
extracellular matrix that composes 80% of the typical IH
lesion; smooth muscle cells compose the remaining 20%.
Autologous saphenous vein grafts remain the conduit
of choice for aortocoronary and peripheral bypasses, with a
patency rate of nearly 60% at 10 years.11 The limited
patency rate of these vascular procedures is due to intimal
hyperplasia development, which leads to late graft occlu-
sion.12 Thus, improvement of the patency rates of these
procedures by inhibition of neointimal thickening is a
major goal in vascular research. To understand the devel-
opment of intimal hyperplasia, different organ culture
models of human saphenous vein have been proposed.13-16
We have recently developed an ex vivo setting designed for
intimal hyperplasia development that uses native human
saphenous vein segments. In this model, the morphologic
and functional integrity of the vessel wall is maintained, and
significant intimal hyperplasia development occurs after 14
days in culture.13,14,17-21
Intercellular communication is responsible for the di-
rect transfer of ions and small molecules from one cell to the
other through gap-junction channels found at cell-cell ap-
positions.22 Molecular cloning studies have shown that gap
junctions are formed by members of a family of transmem-
brane proteins named connexins22 that are involved in
coordinating the electrical and metabolic responses of het-
erogeneous cells.
In the vascular wall, gap junctions show a distribution
in structures that link all of the different cell types.23
Gap-junction proteins may also coordinate the mechanical
contractions of smooth muscle cells to modulate the vaso-
motor tone of the vessel wall. Vasoconstriction and vasodi-
lation waves travel rapidly along the vessel network because
of the conduction through gap junctions of signals between
endothelial or smooth muscle cells (or both).24
Vascular cell gap junctions are essentially composed of
four connexins (Cxs 37, 40, 43, and 45) in various relative
amounts, depending on species and vascular beds.25-27
This mechanism of intercellular communication has a key
role in a variety of vascular functions22,23 and pathologies
where proliferation and migration are important, such as
atherosclerosis,28 endothelial wound repair,29 and regula-
tion of angiogenesis.30
The 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-
CoA) reductase inhibitors (statins) are a class of cholester-
ol-lowering drugs that are used for the prevention and treat-
ment of atherosclerosis.31 In vitro studies have
demonstrated that statins inhibit the proliferation and mi-
gration of rat smooth muscle cells32 and decreased the
neointima formation in organ-cultured human saphenous
vein in association with reducedmatrixmetalloproteinase-9
levels.18,31 Recently, statins have been shown to reduce
Cx43 expression in human vascular cells.28
No study to date has evaluated whether gap-junctional
communication is involved in the process of intimal hyper-
plasia in human. This assertion was investigated by using
the aforementioned organ culture model of intimal hyper-
plasia in human saphenous veins. Here, we show that thedevelopment of intimal hyperplasia was associated with
changes in the expression of Cx43.
MATERIAL AND METHODS
Harvesting of human saphenous vein and vein
culture. Our institutional review committee approved the
study. Surplus 5-cm-long segments of nonvaricose saphe-
nous vein were obtained from 20 patients (mean patient
age, 60 3 years; 20 men) undergoing a lower limb bypass
surgery. The surplus saphenous veins were dissected by
using a minimal touch technique and those used for the
experiment were immediately stored in Krebs solution
without calcium (in mmol/L: NaCl, 118; KCl, 4.7;
MgSO4, 1.2; KHPO4, 1.2; NaHCO3, 25; ethylenediami-
netetraacetic acid [EDTA], 0.026; glucose, 11.1). Two-
centimeter segments of the harvested veins were cut open
longitudinally with luminal surface facing upwards. The
segments were then pinned out onto a Mersilene mesh
(Ethicon) in a Pyrex dish, containing a layer of Sylgard 184
resin (Dow Corning, Seneffe, Belgium) and were cultured
at 37°C in a humidified atmosphere of 95% air, 5% carbon
dioxide. The segments were immersed in about 5mL of the
culture medium (Medium 199 Earle; Biochrom KG) sup-
plemented with 10% newborn calf serum (Gibco BRL) and
1% antibiotic-antimycotic solution (10,000 U/mL penicil-
lin G, 10,000 U/mL streptomycin sulphate, 25 g/mL
amphotericin B, and 5 g/mL gentamicin) (Gibco BRL).
The medium was changed every 2 days for 14 days.13,14
The segments were then rinsed with phosphate-buffered
saline (PBS) and snap frozen. Fluvastatin (Novartis) was
used at a target molarity of 1 M.
Histologic and histomorphometric analysis. Three
5-mm segments of vein were harvested before and after
culture. After fixation in 4% formalin, the vein segments
were paraffin embedded and 5-m-thick sections were
analyzed. Hematoxylin and eosin staining was used for
histologic analysis, and vanGieson-elastin staining was used
for histomorphometric assessment. For histomorphom-
etry, the images were first digitalized and histomorphomet-
ric measurements were performed with specially designed
software (KS 400, Zeiss, Germany) using a standardized
protocol: 24measurements of the intimal andmedial thick-
ness, evenly distributed across the whole section, were
processed on each of two consecutive sections of each
segment at a magnification of 25.
RNA isolation and polymerase chain reaction.
Fragments of the human saphenous vein were homoge-
nized in the Tripure Isolation Reagent (Roche Diagnostics,
Switzerland) using a Kinametic Polytron blender
(Kinametica, Switzerland), and total RNA was extracted
using the kit procedure. For real-time polymerase chain
reaction (RT-PCR), total RNA was treated for 30 minutes
in the presence of DNase I (DNA-free kit, Ambion, Cam-
bridge, UK) and reverse-transcribed using ImProm-II Re-
verse Transcription System (Promega, Switzerland). The
PCR reaction was performed in the presence of 20 ng
sense- and antisense-specific primers using recombinant
Taq DNA polymerase (Gibco-BRL).
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in a PCR machine (Biometra, Switzerland) with the differ-
ent primers were visualized after ethidium bromide staining
on agarose gel. Negative controls included amplification of
distilled water and human vein RNA samples that had not
been reverse-transcribed. The following primers were used:
● human Cx43 (649 bp fragment): 5=-GAACTCAAG-
GTTGCCCAAAC-3= (sense primer) and 5=-TTA-
GAGATGGTGCTTCCCG-3= (antisense primer);
● human Cx40 (416 bp fragment): 5=-TGGAGGT-
GGGCTTCATTGTG-3= (sense primer) and 5=-
TACTTGCTCGGTGACCAGGTTG-3= (antisense
primer);
● human Cx37 (718 bp fragment): 5=-ACGAGCAGT-
CAGATTTCG-3= (sense primer) and 5=-GGATGA-
GAGCCCATTGTAG-3= (antisense primer);
● human Cx45 (570 bp fragment): 5=-GATTGC-
CAAAATGGAGCACG-3= (sense primer) and 5=-
AGGGGGAGCAGATGGTGTATTC-3= (antisense
primer); and
● human glyceraldehyde-3-phosphate dehydrogenase
(GAPDH) (114bp): 5=-AACTTTGGTATCGTG-
GAAGG-3= (sense primer), and 5=-CAGTAGAGG-
CAGGGATGATGT-3= (antisense primer).
Quantitative RT-PCR was performed on total RNA
treated 30 minutes in the presence of DNase I (DNA-free
kit, Ambion, Cambridge, UK) by using a LightCycler
instrument (Roche Diagnostics GmBbH, Mannheim, Ger-
many) and the QuantiTect SYBR Green PCR Kit (Qiagen,
Basel, Switzerland). One-microgram aliquots of DNase-
treated RNA were reverse-transcribed using ImProm-II
Reverse Transcription System (Promega), as described in
the kit protocol. The cDNA samples were subjected to
serial dilutions in water. Each reaction mixture (20 L)
contained 4 L cDNA, 10L 2 PCR Master Mix (con-
taining HotStarTaq DNA Polymerase, buffer, and dNTPs)
and 3 pmol of each primer.
The amplification program consisted of one cycle of 15
minutes at 95°C, followed by 45 cycles of 15 seconds at
95°C, 20 seconds at 50° to 52°C, and 20 seconds at 72°C.
In each run, contamination and specificity of the PCR was
checked by including both a nonreverse-transcribed RNA
sample and a sample of 2 PCR master mix containing 3
pmol of each primer, respectively. Amplification was fol-
lowed by melting curve analysis to verify the identity of the
amplicon.
PCR efficiency was determined by analyzing a dilution
series of the RT-PCR reaction that contained the target
gene and that served as a reference standard. Analysis of
data was performed using the 3.5 version of the Light
Cycler software (Roche Diagnostics GmbH, Germany),
which generated a best-fit line from the log-linear region of
each curve defining the crossing line. The intersection
between the emitted fluorescence and the crossing line
defined the crossing point. The concentration of target
DNA was calculated by plotting the crossing point of eachsample on the standard curves. The cDNA was amplified
using the following primers:
● human Cx43 (123 bp): 5=-TTTCAATGGCTGCTC-
CTC-3= (sense primer) and 5=-TGCTCACTTGCTT-
GCTTGTT-3= (antisense primer);
● human 2 microglobulin (100bp): 5=-TGAGTATGC-
CTGCCGTGTGA-3= (sense primer) and 5=-
GGCATCTTCAAACCTCCATG-3= (antisense prim-
er); and
● humanGAPDH(114bp): 5=-AACTTTGGTATCGTG-
GAAGG-3= (sense primer) and 5’-CAGTAGAGG-
CAGGGATGATGT-3’ (antisense primer).
Data were analyzed with the LightCycler Software
(Roche, Roche Diagnostics).
Western blotting. Fragments of human saphenous
vein were rapidly frozen in liquid nitrogen. Each vein was
pulverized with a pestle and mortar precooled in liquid
nitrogen, and the powder was homogenized and sonicated
in 62.5 mM Tris(hydroxymethyl)aminomethane (pH 6.8),
5% sodium dodecylsulfate, and 10 mM EDTA. Protein
content was determined by Bio-Rad DC Protein Assay
Reagent Kit (Bio-Rad Laboratories).
Aliquots of veins were heated at 50°C in loading buffer,
fractionated by electrophoresis in a 12.5% polyacrylamide
gel, and immunoblotted overnight onto Immobilon poly-
vinylidene fluoride membranes (Millipore Co) at a constant
20V. Membranes were incubated for 1 hour in PBS con-
taining 5% milk and 0.1% Tween 20 and then incubated
overnight at 4°C with an antiserum against Cx43 (antirab-
bit polyclonal antibodies, AB1728, Chemicon) or Cx40
(antirabbit poyclonal antibodies, AB1726, Chemicon) di-
luted 1:200, tubulin, or -actin antihuman smooth muscle
cells (Sigma, St Louis, Mo) diluted 1:2000 in blocking
buffer.
After the immunoblots were rinsed in PBS containing
0.1% Tween 20, they were incubated for 1 hour with
anti-rabbit immunoglobulin (Ig) antibody coupled to alka-
line phosphatase (Dako Diagnostic AG) that was diluted
1:5000. Antigen-antibody complexes were detected with
the HRP Western blot detection system (Amersham). In
these experiments, controls included use of rat lungs and
bovine aorta endothelium.
Immunofluorescence and histochemistry. The hu-
man saphenous veins were cut in fragments that were
quickly frozen in 2-methylbutane precooled in liquid nitro-
gen. Vein fragments were frozen in optimal cutting tempera-
ture medium (Miles Inc) and cryo-sectioned at about 5 m
thickness. Sections were rinsed in PBS, incubated 30 min-
utes in a buffer containing 0.5% bovine serum albumin
(BSA) and 0.2% Triton X-100, and then exposed for 20
hours to antibodies against either Cx43 (AB1728, Chemi-
con), or Cx40 (AB1726, Chemicon) and -smooth muscle
cell actin (A2547, Sigma) diluted 1:500 in PBS. Primary
antibodies were detected using secondary antibodies la-
belled with fluorescein isothiocyanate (Molecular Probes
Inc) and directed against rabbit IgG. Sections were then
rinsed in PBS, counterstained with Evans Blue and cover-
pared with controls (Native); **P  .01.
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munolabeled with antibodies recognizing von Willebrand
factor (Dako diluted 1:1000) or the smooth muscle cells
-actin (diluted 1:1000) (A5441, Sigma). Sections were
viewed on a microscope (Leica).
Statistical analysis. Data were expressed as mean 
SEM. Differences between means were assessed with the
Student’s t test, analysis of variance, or both. Statistical
significance was defined at a value of P .05, P .01, and
P  .001.
RESULTS
An in vitro model of human saphenous vein
hyperplasia. Intimal hyperplasia was induced experimen-
tally using an ex vivo organ culture model of human saphe-
nous veins. Veins were incubated in culture for a period of
14 days. The integrity of the vessel wall was maintained
during the culture period (Fig 1, A and B). The presence of
smoothmuscle cells and endothelial cells was demonstrated
using immunoreactivity for -actin (expressed in smooth
muscle cells, Fig 1, C and D) and for von Willebrand factor
(expressed by endothelial cells, Fig 1, E and F). Quantita-
tive assessment of histomorphometric measurements from
van Gieson-elastin stained sections of six different venous
segments before and after vein culture during a period of 14
days demonstrated a significant increase of the ratio be-
tween intimal andmedial thickness compared to the respec-
tive freshly isolated vein (Fig 1, lower panel).
Increased connexin43 in human saphenous vein in
culture. RT-PCR analysis of freshly isolated human vein
mRNA demonstrated the presence of a transcript for four
connexins (Cx37, Cx40, Cx43, and Cx45) but not for
Cx36 (data not shown). After 14 days in culture, the tran-
script for Cx43 was increased and a similar expression pattern
was observed for the Cx37, Cx40 and Cx45 mRNAs com-
pared with controls (Fig. 2, A). In view of previous reports
on human33 and rabbit34 vascular smooth muscle cells, we
focused our experiments on Cx43, thought to be the
prominent connexin in smooth muscle cells.
Quantitative RT-PCR evaluation of Cx43mRNA expres-
sion normalized with 2 microglobulin or GAPDH (not
shown) in human saphenous vein in culture demonstrated
that hyperplasia was associated with a large increase in the
levels of Cx43 mRNA after 14 days in culture (Fig 2, B).
Western blot analysis of total human vein extracts
showed that Cx43 was expressed as two major immunore-
active forms, with apparent molecular weights of 43 and 44
kDa. Comparison of multiple independent samples showed
that the levels of Cx43 were significantly increased in the
vein after 14 days in culture. Quantitative evaluation of the
two immunoreactive bands revealed that after 14 days in
culture, the levels of Cx43 were increased (P .001) about
eightfold (Fig 2, C and D). The expression of Cx43 rose
between 1 and 3 days in culture, and was greatest at 14 days
(Fig 3). Throughout this period, there was no change in the
levels of Cx40 (Fig 3).
Immunolabeling demonstrated that Cx43 was immu-Fig 1. Upper panel, Development of intimal hyperplasia in hu-
man saphenous vein segments after 14 days in culture. A, Com-
pared with control vein, (B) intimal and subintimal space thick-
ness, corresponding to intimal hyperplasia (IH) is markedly
increased (van Gieson-elastin staining) in human venous segment
after 14 days in culture. C and D, Immunolabeling of the sections
shown in A and B, with antibodies against -actin (brown color)
revealed the presence of smooth muscle cell proliferation in the
neointima (arrows in A, B, C, and D, represent the lamina elastica
interna). E and F, Immunolabeling with antibodies against the
factor VIII demonstrated the presence of endothelial cells along
the vessel. Original magnification, 400 in A, B, C, D and 200
for E and F. L, Lumen; I, intima; IH, intimal hyperplasia; M,
media. Lower panel, Quantitative assessment of six measurements
(one per human vein segment) of intimal and subintimal space
thickness, corresponding to intimal hyperplasia, was significantly
increased in vein segments incubated in culture for 14 days com- nolocated on smooth muscle cells of freshly frozen human
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connexin transcripts are expressed in the human saphenous vein wall. Reverse-transcribed human saphenous vein RNA
was amplified by polymerase chain reaction (PCR) using primers specific for human Cx37, Cx40, Cx43, and Cx45. The
amplification of four amplicons corresponding to Cx37, Cx40, Cx43, and Cx45 are shown after ethidium bromide
staining. These products were not amplified in samples that were not reverse-transcribed before PCR processing (–).
This experiment was performed in triplicate with different human vein segments. B, Expression of Cx43 mRNA
analyzed by quantitative real-time PCR is increased in vein that is developing intimal hyperplasia. Quantitative
assessment of six to sevenmeasurements (one per human vein segment) showed that Cx43mRNAwas increased sixfold
in vein segments cultured during a period of 14 days compared with control veins (Native). Values represent ratios
between Cx43 and 2-microglobulin mRNAs expression. Data are expressed as mean SEM; ***P .001. GAPDH,
glyceraldehyde-3-phosphate dehydrogenase. C and D, Western blot analysis of total proteins showed that the levels of
Cx43 were markedly increased (about 10-fold) in vein after 14 days in culture compared with control levels. Data are
expressed as mean  SEM; P  .001. BA, bovine aorta. Under both conditions, Cx43 was detected as two bands of
43-44 kDa. Each lane represents a sample from a different vein. All lanes were loaded with 75 g total proteins. In the
same samples, levels of tubulin were not modified. As positive control, 25 g of freshly scraped bovine aortic
endothelium was used.
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culture, a marked increase in the number of immunoreac-
tive dots was observed in the smooth muscle cells (Fig 4, E
and G upper panel). Fig 4, C and G (upper panel) also
showed Cx43 expression on both smooth muscle cells and
endothelial cells. Cx40 staining was only observed in the
endothelial layer (Fig 4, H upper panel).
Immunofluorescence labeling of serial sections of the
human saphenous vein before (Fig 4, A and B lower panel)
and after 14 days in culture (Fig 4, C and D lower panel)
was performed using specific antibodies against Cx43 and
-smooth muscle cells. These data revealed that the in-
crease in the number of Cx43 immunofluorescent spots
observed after 14 days in culture occurs mainly in the
smooth muscle cells.
Reduction of intimal hyperplasia and Cx43 expres-
sion in organ culture by fluvastatin. We examined
whether the cholesterol-lowering drug fluvastatin inhibited
the neointima formation in organ-cultured human saphe-
nous vein. Fluvastatin reduced neointimal thickness of
about 50% (P  .01) (Fig 5, A) at a concentration of 1 M
known to have no detrimental effects on cell viability in
saphenous vein organ cultures.18,35 Western blot analysis of
veins segments cultured for 14 days in presence of fluva-
statin demonstrated a marked decrease in the levels of the
two immunoreactive bands corresponding to Cx43 (Fig 5,
B). Cx43 was significantly reduced by 50% to 70% in the
veins incubated in presence of fluvastatin compared with
controls (P  .01) (Fig 5, C).
DISCUSSION
Stenosis due to intimal hyperplasia is the most common
cause of failure of venous bypass grafts. To better under-
stand the development of intimal hyperplasia, we used
saphenous veins harvested from patients undergoing a
Fig 3. Cx43 protein levels change during the development of
intimal hyperplasia in human saphenous vein. Western blot analysis
of total proteins content revealed that the expression of con-
nexin43 (Cx43) in venous samples progressively increased during
the first 3 days of organ culture. In the same samples, no change in
the expression of Cx40 was observed during culture period. All
lanes were loaded with 75 g of total proteins. Each lane repre-
sents a sample from a different vein. As positive controls, 25 g of
bovine aorta (BA) endothelial proteins and 40 g of rat lung (RL)
proteins were used. Levels of tubulin proteins were not modified.lower limb bypass surgery in an ex vivo organ culturemodel. This model maintains the morphologic and func-
tional integrity of the vessel wall and a significant develop-
ment of intimal hyperplasia occurs after 14 days in culture.
We have postulated that gap junctions, which coordinate
physiologic processes such as cell growth and differentiation,
may participate in the development of intimal hyperplasia.
Indeed, intimal hyperplasia consists of proliferation and
migration of smooth muscle cells into the subendothelial
space. This is the first study that evaluates the involvement
of gap junctional communication in the process of intimal
hyperplasia in humans. Our data demonstrate a critical role
for Cx43-mediated gap junctional communication in the
human vein during the development of intimal hyperplasia
in the aforementioned organ culture model.
Gap junction channels provide an enclosed conduit for
direct exchanges of signalling molecules, including ions
and small metabolites, between cells. This system of
communication allows cells to review the functional state of
their neighbors. In vessels, endothelial cells may express
three connexin isotypes, namely Cx37, Cx40, and Cx43,
whereas the underlying smooth muscle cells may express
Cx37, Cx40, Cx43, and Cx45. In most vascular smooth
muscle cells, Cx43 expression and function seem domi-
nant.36-38
Our study investigated the changes in Cx43 expression
that might accompany the development of intimal hyper-
plasia in an in vitro culturemodel of human saphenous vein.
We showed that Cx43, but not Cx40, is markedly overex-
pressed during the 14-day culture period in the smooth
muscle cells and that treatment with fluvastatin caused a
reduction of neointima formation in cultured human sa-
phenous vein segments in association with a marked de-
crease in Cx43 expression. These results provide evidence
that increased Cx43 is associated with the in vitro develop-
ment of intimal hyperplasia in the human vein.
Statins and marimastat have been shown to decrease
intimal hyperplasia by reducing matrix metalloproteinase-9
activity and smooth muscle cell proliferation.17 Recently, it
has been demonstrated that statins reduced Cx43 expres-
sion in primary human vascular cells in vitro,28 and in vivo
studies have further shown an association between reduced
Cx43 expression levels in mice treated with statins and the
presence of a lower number of inflammatory cells in ather-
oma.28 Although we used an in vitro organ culture model,
it uses the exact tissue (saphenous vein) that causes the
clinical problem in vivo and our observations provide the
first report that statins reduced Cx43 expression in human
vascular tissue.
Communication via gap junctions has been implicated
in the regulation of cell growth, differentiation39 and mi-
gration.29,30,40-42 These three processes have a central role
in the development of intimal hyperplasia. Accordingly, we
show that conditions that modify vein homeostasis due to
changes in the proliferation and migration rate of smooth
muscle cells are associated with a marked increase in Cx43
expression. During hyperplasia, the increase of Cx43 is
associated with smooth muscle cell proliferation, and the
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remains to be elucidated.
The finding that the changes in Cx43 expression took
place within few days indicates that the increase in Cx43
expression in smoothmuscle cells is an early event. Changes
in Cx43 levels were also significantly faster than those
required to observe structural wall modifications, such as
smooth muscle cells hyperplasia and migration, suggesting
that alterations of the normal connexin pattern may induce
the subsequent structural and functional changes in the
muscle layer.
The abundance of Cx43 suggests that gap junctional
communication between smooth muscle cells may play a
role in the initiation of the proliferative response and sub-
sequently inmaintaining it. The response of smoothmuscle
cells in the human vein initially involves replication in the
media followed by migration to the neointima, and the
question concerns the relationship between the upregula-
tion of Cx43 and the development of intimal hyperplasia.
Increasing evidence suggests that reduced gap junctional
communication is involved in uncontrolled growth.43-45
Our findings suggest, however, that upregulation of Cx43
in the human vein is linked to smoothmuscle cell activation
and may be a transient event in the cell cycle of the smooth
muscle cell, as has already been observed during vascular
healing in the rat carotid artery.46
Intimal hyperplasia is the process by which the cell
population increases within the innermost layer of the
arterial wall47 such as occurs physiologically in ho-
mografts, transplanted organs,48 and in veins used as
arteriovenous fistulas or arterial bypass grafts.49 It con-
sists of proliferation of the vascular smooth muscle cells
Fig 4. Connexin43 (Cx43) is increased in smooth muscle cells of
human saphenous vein in culture. Upper panel, Phase-contrast
views of sections of human saphenous vein before (B) and after14
days in culture (D, F). Immunofluorescence labeling with specific
antibodies located Cx43 at discrete spots dispersed throughout the
media of the vein wall (A). A sizable increase in the number and
pattern of these spots was noticed in human vein that was devel-
oping hyperplasia after 14 days in culture (C, E). The limited
amount of Cx43 expressed by the endothelial cells is visible in
panel E. Cx43 expression in smooth muscle located in the intimal
hyperplasia cells is visible on panel C and G. Immunofluorescence
labeling with Cx40 antibodies reflected the presence of Cx40 only
in the endothelial cells (H). L, Lumen; I, intima; IH, intimal
hyperplasia; M, media. Original magnification: 400. Lower
panel, Immunofluorescence labeling of serial sections of the hu-
man saphenous vein before (A, B) and after 14 days in culture (C,
D). Alpha-smooth muscle actin was localized in the smooth mus-
cle cells of the human vein (A, C) and demonstrated that Cx43 is
located in the human vein smooth muscle cells (B and D). Cx43
and -smooth muscle staining revealed that the increase in the
number of Cx43 immunofluorescent spots observed after 14 days
in culture occurred in the smooth muscle cells (B, D). Arrows
indicate the presence of -smooth muscle actin in A and C and
Cx43 in B and D. L, Lumen; M, media. Original magnification,
400.
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interna and their secretion of extracellular matrix in the
subendothelial space.
The contractile smooth muscle cells of adult veins
exhibit low rates of proliferation50; they are rarely called
upon migrate to re-establish vascular integrity, but
smooth muscle cells retain the ability to migrate and
divide rapidly in response to injury. Such a change in
behavior requires a switch in the spectrum of active genes
involved for migration and proliferation51 such as the
metalloproteinase31 and the nitric oxide synthase
genes.52 The marked increase of Cx43, already observed
after a few days in cultured veins, suggests that Cx43
might play a role in the initiation step of proliferation
and also during the formation of intimal hyperplasia.
Atherosclerosis, the most common pathophysiologic
process, involves expansion of the intimal vascular smooth
muscle cell population53 together with the accumulation of
lipids and leucocytes.54 Evidence is growing that dysfunc-
tional gap junctional intercellular communication is in-
volved in the development of atherosclerosis.55 Blackburn
et al56 reported that Cx43 expression in intimal smooth
muscle cells was shown to increase at the early stages of
human coronary atherosclerosis and to decrease at later
stages of the disease.56 Recently, it was demonstrated that
the expression of Cx43, Cx40, and Cx37 is altered in athero-
sclerotic plaques57 and that reduced Cx43 levels inhibit the
Fig 5. Fluvastatin decreased intimal hyperplasia and co
A, Quantitative assessment of six measurements (one per
intimal hyperplasia, was significantly decreased in vein se
compared with control veins cultured without fluvastatin
were decreased in vein segments incubated in the pres
evaluation of six immunoblots (one per vein) revealed th
veins incubated with fluvastatin. **P  .01.formation of atherosclerotic lesions in low-density-lipoproteinreceptor-deficient mice.28 These data indicate that Cx43 has a
role in atherosclerotic plaque formation, and a possible mech-
anism may involve Cx43-mediated effects on smooth muscle
cell proliferation or function.55
To proliferate and migrate, vascular smooth muscle
cells should undergo a phenotypic transformation, which is
a key step in neointimal formation. From their resting,
contractile state, they revert to a more embryonic pheno-
type that allows the synthesis of extracellular matrix. Inhi-
bition of this change by transforming growth factor-
(TGF-)58 can prevent the development of intimal hyper-
plasia. It was recently demonstrated that the Cx43-medi-
ated heterocellular gap junction between endothelial and
mesenchymal cells is necessary for contact-dependent acti-
vation of TGF-, which mediates endothelial-induced mu-
ral cell differentiation.59 These data reinforce the hypothe-
sis that increased Cx43 expression plays a role in the
differentiation of smooth muscle cells.38,60,61
In conclusion, our findings represent an important
contribution to the understanding of the mechanisms
involved in the development of intimal hyperplasia by
identifying Cx43 as a target protein that is markedly
increased in intimal hyperplasia. These data also show
that fluvastatin could prevent this induction, supporting
a crucial role for Cx43-mediated gap junctional commu-
nication in the human vein during the development of
n43 (Cx43) levels in human saphenous veins in culture.
an vein segment) of intimal thickness, corresponding to
ts after 14 days in culture in the presence of fluvastatin
 .01. B, Western blot revealed that the levels of Cx43
of fluvastatin compared with controls. C, Quantitative
e levels of Cx43 were decreased threefold to fourfold innnexi
hum
gmen
. **P
ence
at thintimal hyperplasia.
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